person · Reporting owner

Evoli Lisa

Disclosed activity across 2 companies

Tapewire entity: 84906
SEC CIK: 0001661715

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707	EVP & CHRO	March 10, 2023	March 14, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INTEGRA LIFESCIENCES HOLDINGS CORP

Report date March 10, 2023 · Filed March 14, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,446	Ending reported balance After 2023-03-13 transaction · row 8 8 source rows · reconciled sequence Row 1 · 2023-03-10 · Grant · Acquired 2,532 · Balance 21,137 Row 2 · 2023-03-11 · Tax withholding · Disposed 483 · Balance 20,654 Row 3 · 2023-03-11 · Tax withholding · Disposed 277 · Balance 20,377 Row 4 · 2023-03-12 · Tax withholding · Disposed 448 · Balance 19,929 Row 5 · 2023-03-12 · Tax withholding · Disposed 269 · Balance 19,660 Row 6 · 2023-03-12 · Tax withholding · Disposed 255 · Balance 19,405 Row 7 · 2023-03-13 · Tax withholding · Disposed 659 · Balance 18,746 Row 8 · 2023-03-13 · Tax withholding · Disposed 300 · Balance 18,446
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.87 · Expires 2031-03-10	Direct	6,201	Reported balance After 2023-03-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-03-10 · Grant · Acquired 6,201 · Balance 6,201 F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Catalent, Inc.

Report date December 18, 2024 · Filed December 18, 2024

Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-12-18 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-12-18 · Disposition to issuer · Disposed 39,366 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Row 2 · 2024-12-18 · Grant · Acquired 12,032 · Balance 12,032 F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time. Row 3 · 2024-12-18 · Disposition to issuer · Disposed 12,032 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration.
Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $46.51 · Expires 2033-08-01	Direct	0	Reported balance After 2024-12-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-12-18 · Disposition to issuer · Disposed 14,225 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").

F2: Includes restricted stock units ("RSUs").

F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").

F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.

F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time.

F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration.

F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 18, 2024 Filed Dec 18, 2024 11:11 UTC	Catalent, Inc. CTLT · Entity 16279	Disposition to issuerOptions to purchase Common Stock · Derivative	14,225	Not disclosed Strike: $46.51	Not disclosed	Disclosure SEC source: 0000950170-24-137656 · ownership.xml · derivative · entry 4 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,225 shares Expires 2033-08-01 F1 · kind: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F7 · price: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option. F7 · derivative.exercise_date: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option. Read SEC document
December 18, 2024 Filed Dec 18, 2024 11:11 UTC	Catalent, Inc. CTLT · Entity 16279	Disposition to issuerCommon Stock	12,032	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-137656 · ownership.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F6 · price: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration. Read SEC document
December 18, 2024 Filed Dec 18, 2024 11:11 UTC	Catalent, Inc. CTLT · Entity 16279	GrantCommon Stock	12,032	$0.00	$0.00	Disclosure SEC source: 0000950170-24-137656 · ownership.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,032 F5 · shares: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time. Read SEC document
December 18, 2024 Filed Dec 18, 2024 11:11 UTC	Catalent, Inc. CTLT · Entity 16279	Disposition to issuerCommon Stock	39,366	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-137656 · ownership.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: Includes restricted stock units ("RSUs"). F3 · price: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4 · price: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Read SEC document
August 02, 2024 Filed Aug 5, 2024 12:39 UTC	Catalent, Inc. CTLT · Entity 16279	SaleCommon Stock	3,859	$59.67	$230,266.53	Disclosure SEC source: 0001596783-24-000068 · wk-form4_1722875991.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,366 F1 · shares: Shares sold by the reporting person through an automatic sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuers omnibus incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $59.495 to $59.785, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units. Read SEC document
July 26, 2024 Filed Jul 30, 2024 17:04 UTC	Catalent, Inc. CTLT · Entity 16279	GrantCommon Stock	15,338	$0.00	$0.00	Disclosure SEC source: 0001596783-24-000056 · wk-form4_1722373433.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,225 F1 · shares: Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur in three equal annual installments beginning on July 26, 2025. F2 · balance_after: Includes RSUs. Read SEC document
March 13, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	300	$52.61	$15,783.00	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 8 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,446 Read SEC document
March 13, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	659	$52.61	$34,669.99	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 7 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,746 Read SEC document
March 12, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	255	$52.87	$13,481.85	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 6 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,405 Read SEC document
March 12, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	269	$52.87	$14,222.03	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,660 Read SEC document
March 12, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	448	$52.87	$23,685.76	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,929 Read SEC document
March 11, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	277	$52.87	$14,644.99	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,377 Read SEC document
March 11, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	483	$52.87	$25,536.21	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,654 Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantNon-Qualified Stock Option (right to buy) · Derivative	6,201	$0.00 Strike: $52.87	$0.00	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · derivative · entry 9 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,201 Underlying: Common Stock · 6,201 shares Expires 2031-03-10 F1 · derivative.exercise_price: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:14 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	2,532	$0.00	$0.00	Disclosure SEC source: 0001209191-23-018420 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,137 Read SEC document
February 27, 2023 Filed Feb 28, 2023 21:29 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	3,767	$57.00	$214,730.68	Disclosure SEC source: 0001209191-23-013669 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,605 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $57 to $57.08. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:07 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	1,137	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009704 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,372 F3 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 11, 2022 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 11, 2023, the first anniversary of the grant date. Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:07 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	1,054	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009704 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,235 F2 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 12, 2021 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2023, the second anniversary of the grant date. Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:07 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	632	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009704 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,181 F2 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 12, 2021 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2023, the second anniversary of the grant date. Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:07 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	1,552	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009704 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · EVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,549 F1 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 13, 2020 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 34% of the shares will vest on March 13, 2023, the third anniversary of the grant date. Read SEC document
August 10, 2022 Filed Aug 11, 2022 20:19 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	1,165	$55.81	$65,019.58	Disclosure SEC source: 0001209191-22-045420 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,997 Read SEC document
August 03, 2022 Filed Aug 5, 2022 20:58 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	293	$55.34	$16,214.62	Disclosure SEC source: 0001209191-22-044590 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,162 Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:39 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	456	$56.87	$25,932.72	Disclosure SEC source: 0001209191-22-044200 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,455 Read SEC document
June 15, 2022 Filed Jun 16, 2022 21:08 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	900	$55.93	$50,337.00	Disclosure SEC source: 0001209191-22-037513 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,911 Read SEC document
May 24, 2022 Filed May 25, 2022 20:23 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	250	$59.85	$14,962.53	Disclosure SEC source: 0001209191-22-031863 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,811 Read SEC document
March 13, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	704	$65.11	$45,837.44	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 9 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,061 Read SEC document
March 13, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	430	$65.11	$27,997.30	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 8 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,765 Read SEC document
March 13, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	115	$65.11	$7,487.65	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 7 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 Read SEC document
March 13, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	188	$65.11	$12,240.68	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 6 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,310 Read SEC document
March 12, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	657	$65.11	$42,777.27	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,498 Read SEC document
March 12, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	394	$65.11	$25,653.34	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,155 Read SEC document
March 12, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	164	$65.11	$10,678.04	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,549 Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,553	$0.00 Strike: $65.11	$0.00	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · derivative · entry 10 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,553 Underlying: Common Stock · 5,553 shares Expires 2030-03-11 F1 · derivative.exercise_price: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2022. F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2022. Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	7,680	$0.00	$0.00	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,713 Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:42 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	1,975	$0.00	$0.00	Disclosure SEC source: 0001209191-22-018843 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,033 Read SEC document
February 28, 2022 Filed Mar 1, 2022 22:01 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	1,254	$67.03	$84,055.62	Disclosure SEC source: 0001209191-22-014101 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,058 Read SEC document
February 11, 2022 Filed Feb 14, 2022 21:40 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	3,830	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009311 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,312 F3 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 12, 2021 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2022 at 200% of target, the first anniversary of the grant date. Read SEC document
February 11, 2022 Filed Feb 14, 2022 21:40 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	2,566	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009311 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,482 F2 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2020 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2022 at 150% of target, the second anniversary of the grant date. Read SEC document
February 11, 2022 Filed Feb 14, 2022 21:40 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	1,566	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009311 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,916 F1 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2019 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 34% of the shares will vest on March 13, 2022 at 150% of target, the third anniversary of the grant date. Read SEC document
August 03, 2021 Filed Aug 3, 2021 21:12 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	189	$70.62	$13,347.18	Disclosure SEC source: 0001209191-21-049397 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,350 Read SEC document
August 01, 2021 Filed Aug 3, 2021 21:12 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Tax withholdingCommon Stock	286	$72.39	$20,703.54	Disclosure SEC source: 0001209191-21-049397 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,539 Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,745	$0.00 Strike: $55.91	$0.00	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · derivative · entry 6 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,746 Underlying: Common Stock · 2,745 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2019. Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,590	$0.00 Strike: $43.39	$0.00	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · derivative · entry 5 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,771 Underlying: Common Stock · 2,590 shares Expires 2028-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2020. Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	2,745	$75.00	$205,875.00	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825 Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionCommon Stock	2,745	$55.91	$153,472.95	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	2,590	$75.00	$194,250.00	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825 Read SEC document
May 10, 2021 Filed May 11, 2021 20:31 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionCommon Stock	2,590	$43.39	$112,380.10	Disclosure SEC source: 0001209191-21-031687 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 14, 2021 Filed Apr 15, 2021 20:11 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,440	$0.00 Strike: $56.23	$0.00	Disclosure SEC source: 0001209191-21-026819 · doc4.xml · derivative · entry 7 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147 Underlying: Common Stock · 3,440 shares Expires 2026-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2018. Read SEC document
April 14, 2021 Filed Apr 15, 2021 20:11 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,785	$0.00 Strike: $43.68	$0.00	Disclosure SEC source: 0001209191-21-026819 · doc4.xml · derivative · entry 6 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,785 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · derivative.exercise_date: 25% of the stock options vested every first, second, third and fourth anniversaries of the grant date of 3/13/2017. Read SEC document
April 14, 2021 Filed Apr 15, 2021 20:11 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	1,785	$70.00	$124,950.00	Disclosure SEC source: 0001209191-21-026819 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.